Deal facts
- Buyer
- Mallinckrodt
- Target
- Endo
- Deal value
- Not disclosed
- Announced
- 1 August 2025
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Mallinckrodt completes acquisition of Endo
Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the Introduction of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth in the Introduction and Item 2.01 of this Current Report on Form 8-K
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC
CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…
- Buyer
- CCP PAW 2 LIMITED
- Target
- ANIMALCARE GROUP PLC
- Deal value
- Not disclosed
- Deal type
- going private
argenx BV to acquire Forte Biosciences, Inc.
argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing…
- Buyer
- argenx BV
- Target
- Forte Biosciences, Inc.
- Deal value
- USD 2,200,000,000
- Deal type
- going private
Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6…
- Buyer
- Vertex Pharmaceuticals Incorporated
- Target
- Crinetics Pharmaceuticals, Inc.
- Deal value
- USD 10,000,000,000
- Deal type
- going private
Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.
Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…
- Buyer
- Trafalgar Asset Management, LLC
- Target
- The Greater Cannabis Company, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.
Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…
- Buyer
- Hanmi Pharmaceuticals Co. Ltd.
- Target
- Aptose Biosciences Inc.
- Deal value
- USD 3,466,470
- Deal type
- going private
Buyer history
Mallinckrodt
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive